Tieton Capital Management LLC Invests $6.41 Million in Niagen Bioscience, Inc. $NAGE

Tieton Capital Management LLC purchased a new stake in Niagen Bioscience, Inc. (NASDAQ:NAGE) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,008,470 shares of the company’s stock, valued at approximately $6,407,000. Niagen Bioscience makes up 1.8% of Tieton Capital Management LLC’s investment portfolio, making the stock its 23rd largest holding.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NAGE. New York State Teachers Retirement System purchased a new stake in Niagen Bioscience in the 4th quarter valued at $30,000. Ameritas Investment Partners Inc. purchased a new position in shares of Niagen Bioscience during the 3rd quarter worth $45,000. Quantbot Technologies LP purchased a new position in shares of Niagen Bioscience during the 3rd quarter worth $48,000. Stoneridge Investment Partners LLC acquired a new position in shares of Niagen Bioscience during the 2nd quarter valued at about $49,000. Finally, Kestra Advisory Services LLC acquired a new position in shares of Niagen Bioscience during the 4th quarter valued at about $70,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience Trading Up 3.6%

Shares of NASDAQ:NAGE opened at $3.17 on Thursday. The business has a 50-day moving average price of $3.31 and a 200 day moving average price of $4.13. The company has a market capitalization of $252.46 million, a price-to-earnings ratio of 17.61 and a beta of 2.09. Niagen Bioscience, Inc. has a 12-month low of $2.87 and a 12-month high of $10.52.

Niagen Bioscience (NASDAQ:NAGE) last posted its earnings results on Tuesday, August 4th. The company reported $0.01 EPS for the quarter, meeting analysts’ consensus estimates of $0.01. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. The company had revenue of $29.78 million for the quarter, compared to analysts’ expectations of $29.95 million. As a group, equities research analysts predict that Niagen Bioscience, Inc. will post 0.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on NAGE. Canaccord Genuity Group dropped their price objective on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. HC Wainwright reiterated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, July 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research note on Friday, July 17th. Roth Capital restated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $10.33.

Niagen Bioscience Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.